Merck & Co., Inc. (LON:0QAH)

London flag London · Delayed Price · Currency is GBP · Price in USD
99.90
-1.37 (-1.35%)
Dec 5, 2025, 5:11 PM BST
-2.06%
Market Cap 185.77B
Revenue (ttm) 47.79B
Net Income (ttm) 14.16B
Shares Out n/a
EPS (ttm) 5.62
PE Ratio 13.12
Forward PE 11.12
Dividend 2.45 (2.46%)
Ex-Dividend Date Sep 15, 2025
Volume 26,921
Average Volume 29,811
Open 101.00
Previous Close 101.27
Day's Range 99.76 - 102.50
52-Week Range 70.15 - 106.06
Beta 0.32
RSI 62.38
Earnings Date Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QAH
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.